newsThe approval of Pemazyre® (pemigatinib) was based on Phase II…
30 March 2021 | By Hannah Balfour (European Pharmaceutical Review)
The approval of Pemazyre® (pemigatinib) was based on Phase II trial results in which the treatment met its primary endpoint, demonstrating a 37 percent overall response rate.